Trial Profile
A phase 1 double-blind, placebo-controlled, parallel group study in healthy male subjects to investigate safety, tolerability and pharmacokinetics after multiple ascending (MAD) oral doses of IMU-838
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 May 2020
Price :
$35
*
At a glance
- Drugs Vidofludimus calcium (Primary)
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Pharmacokinetics
- 02 May 2020 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 16 Jan 2018 New trial record